Deborah Shenkman, RDLD, CDCES

August 02, 2024

The panel concludes its discussion with key takeaways on the optimal care of patients with type 1 diabetes care and thoughts on unmet needs within the treatment space.

August 02, 2024

Focusing on logistical matters as it pertains to teplizumab administration, the panel discusses infusion site considerations, insurance coverage hurdles, and the process of getting patients approved.

August 02, 2024

Diabetes specialists outline the patient selection protocol for teplizumab and describe the teplizumab infusion process.

August 02, 2024

Experts on type 1 diabetes discuss the availability of local medical facilities that offer teplizumab screening and evaluation services for individuals at risk of progression of disease.

August 02, 2024

Amy Burton, MD, reviews findings from the TN-10 study investigating teplizumab, an anti-CD3 monoclonal antibody, for prevention of diabetes in relatives at risk for T1D.

August 02, 2024

Diabetes experts discuss the important role of teplizumab in delaying the onset of type 1 diabetes and provide insights on the drug’s mechanism of action.

August 02, 2024

Following audience polls, the panelists provide clinical insights into their screening practices for patients with type 1 diabetes, highlighting key antibodies they screen for.

August 02, 2024

Audience polls provide the panel insights into common screening practices for patients with type 1 diabetes.

August 02, 2024

The panel outlines the stages of type 1 diabetes, focusing on the importance of early intervention to prevent complications of the disease.

August 02, 2024

A panel of experts on type 1 diabetes (T1D) describe the prevalence and burden of the disease, highlighting the emotional and socio-economic burden extending beyond medical expenses.